Close
Nordic 9Nordic 9

Tekla Capital Management (investor - Private Equity)

United States teklacap.com
See something wrong or missing? Let us know
Offices:Boston

Tekla Capital Management LLC is a registered investment adviser based in Boston, Massachusetts and is the investment adviser for four closed-end funds, Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. The Funds predominately invest in the securities of public and private healthcare companies.

Average round investment:80.72M USD
Average number per year:1.2
Distribution: 2023 (1)2021 (2)2020 (1)2019 (1)
Portfolio companies: France Amolyt PharmaUnited Kingdom Quell TherapeuticsIceland Oculis Pharma See the entire list
Mostly invests in: Iceland Iceland (2) Pharma (3)
See the entire list

Showing 3 of 5 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Tekla Capital Management

Name Criteria
United States Arch Venture Partners
79%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Ireland
  • Average number of deals per year: 1.2
United States What If Ventures
79%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Pharma, Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
Canada CTI Life Sciences
79%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Pharma, Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: France, United Kingdom
  • Average number of deals per year: 1.3
United States Deerfield Management
79%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Pharma, Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
United States Kairos
79%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
United States Longwood Fund
79%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Pharma, Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
United Kingdom Medicxi
79%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Pharma, Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Ireland
  • Average number of deals per year: 1.0
Ireland KCK Group
79%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Ireland
  • Average number of deals per year: 1.5
Germany Evotec AG
79%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Pharma, Health services, Biotech
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Ireland
  • Average number of deals per year: 1.0
China GT Healthcare Capital
79%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Pharma, Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: France, United Kingdom
  • Average number of deals per year: 1.0
Top